Free Trial
NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

NRx Pharmaceuticals logo
$2.96 +0.19 (+6.65%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

Key Stats

Today's Range
$2.70
$3.00
50-Day Range
$1.71
$2.78
52-Week Range
$1.10
$6.01
Volume
652,923 shs
Average Volume
647,671 shs
Market Capitalization
$51.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.50
Consensus Rating
Buy

Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

NRXP MarketRank™: 

NRx Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 675th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NRx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about NRx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NRx Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NRx Pharmaceuticals is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    8.47% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 2.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    NRx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NRx Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.47% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 2.42%, indicating that investor sentiment is improving.
  • News Sentiment

    NRx Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for NRXP on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.27% of the stock of NRx Pharmaceuticals is held by institutions.

  • Read more about NRx Pharmaceuticals' insider trading history.
Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRXP Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
See More Headlines

NRXP Stock Analysis - Frequently Asked Questions

NRx Pharmaceuticals' stock was trading at $2.20 at the beginning of the year. Since then, NRXP shares have increased by 27.0% and is now trading at $2.7950.
View the best growth stocks for 2025 here
.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. The firm had revenue of $1.14 million for the quarter, compared to analysts' expectations of $1.14 million.
Read the conference call transcript
.

Shares of NRx Pharmaceuticals reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

NRx Pharmaceuticals' top institutional investors include Anson Funds Management LP (6.85%) and Simplex Trading LLC. Insiders that own company stock include Daniel C Javitt, Jonathan C Javitt, Chaim Hurvitz, Aaron Gorovitz, Stephen H Willard and Patrick John Flynn.
View institutional ownership trends
.

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/15/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.50
High Stock Price Target
$46.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+925.2%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.38) per share
Price / Book
-2.01

Miscellaneous

Free Float
12,717,000
Market Cap
$47.89 million
Optionable
Optionable
Beta
1.44
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NRXP) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners